zk1414997.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report: May 22, 2014

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
 
98-0351734
(Commission File Number)
 
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
 
31905
(Address of Principal Executive Offices)
 
(Zip Code)

011 972 74 710 7171
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 22, 2014. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
 
For
   
Against
   
Abstain
   
Broker Non-Votes
 
                         
Zami Aberman
   
15,225,574
     
3,653,462
     
26,907
     
15,245,366
 
                                 
Israel Ben-Yoram
   
18,611,618
     
130,728
     
163,597
     
15,245,366
 
                                 
Isaac Braun
   
18,667,408
     
72,388
     
166,147
     
15,245,366
 
                                 
Mark Germain
   
18,604,030
     
138,105
     
163,808
     
15,245,366
 
                                 
Moria Kwiat
   
18,602,861
     
143,824
     
159,258
     
15,245,366
 
                                 
Hava Meretzki
   
18,635,058
     
136,101
     
134,784
     
15,245,366
 
                                 
Nachum Rosman
   
18,631,094
     
109,942
     
164,907
     
15,245,366
 
                                 
Doron Shorrer
   
16,241,054
     
2,505,521
     
159,368
     
15,245,366
 
 
Proposal No. 2 — Amendment to the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock
 
For
   
Against
   
Abstain
   
Broker Non-Votes
 
                     
30,674,537
   
2,725,415
   
177,798
   
573,559
 
 
Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2014

For
   
Against
   
Abstain
   
Broker Non-Votes
 
                     
32,771,414
   
393,910
   
184,128
   
N/A
 

The results reported above are final voting results.

 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
   
Date: May 22, 2014
By:
/s/ Boaz Gur-Lavie
 
Name:
Boaz Gur-Lavie
 
Title:
Chief Financial Officer and Secretary